ASP Isotopes Inc. Common Stock
Financials
Valuation Metrics
ASP Isotopes Inc. Common Stock's Market Cap is $497M. At end of 2025 it was $474M. Ranked #2799 of 3,121 in US market (top 90%), #1227 of 1,463 on NASDAQ (top 84%), #162 of 173 in Materials (top 94%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $497M | US#2,799/3,121 Sec#162/173 |
| Revenue | $31M | US#2,809/3,121 Sec#152/173 |
| Net Income | $-132M | US—/3,121 Sec—/173 |
| Total Assets | $572M | US#2,715/3,121 Sec#153/173 |
| Net Assets | $265M | US#2,577/3,121 Sec#150/173 |
| Employees | 271 | US#2,439/3,121 Sec#133/173 |
| Value | ||
| P/B | 1.88x | US#1,153/3,121 Sec#67/173 |
| P/S | 16.13x | US#2,813/3,121 Sec#152/173 |
| FCF Yield | -16.80% | US—/3,121 Sec—/173 |
| Profitability | ||
| ROE | -49.89% | US#2,681/3,121 Sec#160/173 |
| ROA | -23.08% | US#2,834/3,121 Sec#163/173 |
| Op. Margin | -312.31% | US#2,791/3,121 Sec#152/173 |
| Revenue Growth | 573.40% | US#30/3,121 Sec#1/173 |
| Financial Health | ||
| Debt Ratio | 112.30% | US#1,211/3,121 Sec#106/173 |
| Total Debt | $270M | US#2,143/3,121 Sec#121/173 |
| FCF | $-84M | US#2,603/3,121 Sec#148/173 |
| Cash | $220M | US#1,662/3,121 Sec#100/173 |
| Current Ratio | 3.87x | US#597/3,121 Sec#31/173 |
| Performance | ||
| 1Y Return | -62.91% | US#3,030/3,121 Sec#171/173 |
| 1M Return | -15.93% | US#2,851/3,121 Sec#167/173 |
| From 52W High | -77.61% | US#3,066/3,121 Sec#170/173 |
| 1Y MDD | -77.58% | US#3,045/3,121 Sec#170/173 |
| Trading | ||
| Volume | 3,268,129 shares | US#527/3,121 Sec#37/173 |
| Trading Value | $11M | US#2,306/3,121 Sec#128/173 |
| Per Share | ||
| EPS | $-0.86 | US—/3,121 Sec—/173 |
| BPS | $1.73 | US#2,600/3,121 Sec#145/173 |
Company Info
ASP Isotopes Inc. is an emerging advanced materials company, currently in its pre-commercial stage. This firm is dedicated to the comprehensive management of isotopes, encompassing their creation, dissemination, promotion, and eventual sale. The company's developmental portfolio includes Molybdenum-100, a non-radioactive isotope designed for medical applications, alongside Carbon-14 and Silicon-28. Furthermore, ASP Isotopes is involved with Uranium-235, a specific uranium isotope considered crucial for the carbon-free energy sector. Established in 2021, the company maintains its headquarters in Boca Raton, Florida.